199 related articles for article (PubMed ID: 22998742)
21. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
22. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.
Iovieno N; Papakostas GI
J Clin Psychiatry; 2012 Oct; 73(10):1300-6. PubMed ID: 23140647
[TBL] [Abstract][Full Text] [Related]
23. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
24. Validation of the sleep impact scale in patients with major depressive disorder and insomnia.
Lasch K; Joish VN; Zhu Y; Rosa K; Qiu C; Crawford B
Curr Med Res Opin; 2009 Jul; 25(7):1699-710. PubMed ID: 19505198
[TBL] [Abstract][Full Text] [Related]
25. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
[TBL] [Abstract][Full Text] [Related]
26. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
[TBL] [Abstract][Full Text] [Related]
27. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
Levitan RD; Shen JH; Jindal R; Driver HS; Kennedy SH; Shapiro CM
J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398
[TBL] [Abstract][Full Text] [Related]
28. Buspirone in major depression: a controlled study.
Rickels K; Amsterdam JD; Clary C; Puzzuoli G; Schweizer E
J Clin Psychiatry; 1991 Jan; 52(1):34-8. PubMed ID: 1988416
[TBL] [Abstract][Full Text] [Related]
29. Co-administration of a nitric oxide synthase inhibitor and melatonin exerts an additive antidepressant-like effect in the mouse forced swim test.
Ergün Y; Ergün UG; Orhan FO; Küçük E
Med Sci Monit; 2006 Sep; 12(9):BR307-12. PubMed ID: 16940926
[TBL] [Abstract][Full Text] [Related]
30. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial.
Bech P; Fava M; Trivedi MH; Wisniewski SR; Rush AJ
Acta Psychiatr Scand; 2012 Apr; 125(4):342-8. PubMed ID: 22077211
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
Tedeschini E; Levkovitz Y; Iovieno N; Ameral VE; Nelson JC; Papakostas GI
J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025
[TBL] [Abstract][Full Text] [Related]
32. Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study.
Siwek M; Dudek D; Paul IA; Sowa-Kućma M; Zieba A; Popik P; Pilc A; Nowak G
J Affect Disord; 2009 Nov; 118(1-3):187-95. PubMed ID: 19278731
[TBL] [Abstract][Full Text] [Related]
33. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
Iovieno N; Tedeschini E; Bentley KH; Evins AE; Papakostas GI
J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
[TBL] [Abstract][Full Text] [Related]
34. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
[TBL] [Abstract][Full Text] [Related]
35. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
[TBL] [Abstract][Full Text] [Related]
36. Prolactin response to buspirone is not impaired in drug-naïve first episode patients with major depressive disorder.
Cubała WJ; Landowski J
J Affect Disord; 2014 Jan; 152-154():468-73. PubMed ID: 24035672
[TBL] [Abstract][Full Text] [Related]
37. Low Doses of Ketamine and Melatonin in Combination Produce Additive Antidepressant-like Effects in Mice.
Estrada-Reyes R; Quero-Chávez DB; Trueta C; Miranda A; Valdés-Tovar M; Alarcón-Elizalde S; Oikawa-Sala J; Argueta J; Constantino-Jonapa LA; Muñoz-Estrada J; Dubocovich ML; Benítez-King G
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502152
[TBL] [Abstract][Full Text] [Related]
38. [The current concept of augmentation of treatment efficiency with antidepressant medication].
Damulin IV; Suvorova IA
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(3):106-112. PubMed ID: 26171486
[TBL] [Abstract][Full Text] [Related]
39. Melatonin treatment of winter depression: a pilot study.
Lewy AJ; Bauer VK; Cutler NL; Sack RL
Psychiatry Res; 1998 Jan; 77(1):57-61. PubMed ID: 10710176
[TBL] [Abstract][Full Text] [Related]
40. Augmentation of antidepressant therapy by buspirone: three geriatric case histories.
Robillard M; Lieff S
Can J Psychiatry; 1995 Dec; 40(10):639-40. PubMed ID: 8681264
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
